The antibiotic minocycline increases the lifespan of aged roundworms and prevents the buildup of proteins, revealing a protective mechanism that could be exploited therapeutically to help prevent neurodegenerative diseases.
Now, scientists at Scripps Research have found that minocycline can increase the lifespan of roundworms by preventing the buildup of proteins during aging, according to a study in the open-access journal eLife reports.
Protein aggregation causes several progressive age-related brain diseases, including amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s and prion diseases. The Scripps Research study shows that minocycline prevents this buildup even in older animals with age-impaired stress-response pathways.
The number of proteins in a cell is balanced by the rate of protein manufacture and disposal, called proteostasis. As we age, proteostasis becomes impaired.
“It would be great if there were a way to enhance proteostasis and extend lifespan and health, by treating older people at the first sign of neurodegenerative symptoms or disease markers such as protein build-up,” says lead author Gregory Solis, a graduate student at Scripps Research. “In this study, we investigated whether minocycline can reduce protein aggregation and extend lifespan in animals that already have impaired proteostasis.”
The team first tested 21 different molecules known to extend lifespan in young and old Caenorhabditis elegans (C. elegans) worms. They found that all of these molecules prolonged the lives of young worms, however, the only drug that worked on the older worms was minocycline.
To find out why, the researchers looked at whether minocycline had any effect on protein aggregation in the worms. They treated young and old worms with water or minocycline and then measured two proteins, ?-synuclein and amyloid-?, which are known to build up in Parkinson’s and Alzheimer’s, respectively. Regardless of the worms’ age, those treated with minocycline had reduced aggregation of both proteins as they grew older.
The team next turned their attention to the mechanism behind this discovery. First, they looked at whether minocycline switches on stress-signaling proteins that are impaired in older worms, but they found the drug actually reduces their activity. Next, they studied whether it turns off the cell’s protein-disposal processes, but this was not its mode of action either.
When researchers used a chemical probe to see how minocycline affects the major protein-regulating molecules in the cell, it revealed that minocycline directly affects the protein-manufacturing machinery of the cell, known as the ribosome. This was true in worms, as well as in mouse and human cells.
Finally, the team used worms with increased or decreased protein-manufacturing activity and studied how this altered the effect of minocycline on protein levels and lifespan. As predicted, in mutant worms where protein manufacturing was already decreased, they found a lower dose of minocycline was needed to further reduce protein levels and extend lifespan. In worms where protein manufacturing was increased, the opposite was seen. This suggested that minocycline extends lifespan by controlling the rate of protein manufacturing at the ribosome.
“We have identified minocycline as a drug that can extend lifespan and improve protein balance in already-aging worms,” says Michael Petrascheck, PhD, senior author of the paper and associate professor at Scripps Research. “Our study reveals how minocycline prevents protein aggregation and lays the foundations for drug development efforts aimed at optimizing this already-approved drug for a range of neurodegenerative diseases.”
The Latest on: Minocycline
via Google News
The Latest on: Minocycline
- Minocycline Hydrochloride Market 2020 Analysis by CIPAN, Zeonpharma, Hovione, Tecoland, Ogene Systems, moreon June 15, 2020 at 5:04 am
Global Minocycline Hydrochloride Market report gives COVID-19 Outbreak study aggregated to offer latest bits of knowledge about intense highlights of the Minocycline Hydrochloride Industry.
- An Open-label Pilot Trial of Minocycline in Children as a Treatment for Angelman Syndromeon June 14, 2020 at 5:00 pm
However, this has not precluded the investigation of minocycline (with associated benefit) on human neurological diseases such as Alzheimer's, Parkinson's, Stroke, traumatic brain injuries and ...
- FDA OKs Menlo minocycline foam for inflammatory skin conditionon May 29, 2020 at 12:25 pm
The FDA approves Menlo Therapeutics' (MNLO-4.8%) Zilxi (minocycline) topical foam, 1.5% for the treatment of adults with inflammatory lesions associated with rosacea, a skin condition ...
- Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosaceaon May 29, 2020 at 8:51 am
ZILXI, developed as FMX103 by Menlo's wholly-owned subsidiary Foamix Pharmaceuticals Ltd. ("Foamix"), is the first minocycline product of any kind to be approved by the FDA for use in rosacea.
- Menlo Therapeutics Receives FDA Approval of ZILXI(TM) (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosaceaon May 29, 2020 at 8:50 am
ZILXI, developed as FMX103 by Menlo’s wholly-owned subsidiary Foamix Pharmaceuticals Ltd. (“Foamix”), is the first minocycline product of any kind to be approved ...
- ZILXI™ Now Approved for Inflammatory Lesions of Rosacea in Adultson May 28, 2020 at 5:00 pm
ZILXI, developed as FMX103 by Menlo’s wholly-owned subsidiary Foamix Pharmaceuticals Ltd. (“Foamix”), is the first minocycline product of any kind to be approved by the FDA for use in rosacea.
- Menlo Therapeutics Announces Covered Status for AMZEEQ® (minocycline) topical foam, 4%, on Additional Commercial Formularyon May 27, 2020 at 9:23 am
Minocycline, a broad-spectrum antibiotic known for its efficacy in treating moderate to severe acne, has not previously been available as a topical treatment due to its instability in traditional ...
- Menlo Therapeutics Announces Covered Status for AMZEEQ(R) (minocycline) topical foam, 4%, on Additional Commercial Formularyon May 27, 2020 at 2:04 am
The MarketWatch News Department was not involved in the creation of this content. BRIDGEWATER, May 27, 2020 (GLOBE NEWSWIRE via COMTEX) -- Coverage Effective Immediately on One of the Largest ...
via Bing News